



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification⁵ : A61L 15/44	A1	(11) International Publication Number: WO 92/05111 (43) International Publication Date: 16 April 1992 (16.04.92)
(21) International Application Number: PCT/GB91/01730 (22) International Filing Date: 4 October 1991 (04.10.91) (30) Priority data: 9021674.8 5 October 1990 (05.10.90) GB (71) Applicant (for all designated States except US): ETHICAL PHARMACEUTICALS LIMITED [GB/GB]; Cambridgeshire Business Park, Angel Drove, Ely, Cambs CB7 4EE (GB). (72) Inventor; and (75) Inventor/Applicant (for US only): JENKINS, Anthony, William [GB/GB]; Bridge Farm, West Street, Comberton, Cambridge CB3 7DS (GB). (74) Agent: BOULT, WADE & TENNANT; 27 Furnival Street, London EC4A 1PQ (GB).		(81) Designated States: AT (European patent), AU, BE (European patent), CA, CH (European patent), DE (European patent), DK (European patent), ES (European patent), FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, LU (European patent), NL (European patent), NO, SE (European patent), US. Published <i>With international search report.</i>
(54) Title: TRANSDERMAL DEVICE (57) Abstract A method of preparing a device for transdermal delivery of an active ingredient which is solid at room temperature and in which part or all of the active ingredient is present in a saturated or supersaturated solution is provided in which as a first step a mixture is prepared which includes at least a polymer adhesive, a vehicle for the polymer adhesive, the active ingredient and a solvent mixture for the active ingredient comprising at least two solvents. The mixture is formed into a film and dried. The vehicle for the polymer adhesive and at least one of the solvents in the solvent mixture for the active ingredient have boiling points below the drying temperature while at least one of the solvents in the solvent mixture for the active ingredient has a boiling point above the drying temperature, the solubility of the active ingredients in the high boiling solvent or solvents being greater than 0.5 %.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland			SN	Senegal
CI	Côte d'Ivoire	KR	Republic of Korea	SU ⁺	Soviet Union
CM	Cameroon	LI	Liechtenstein	TD	Chad
CS	Czechoslovakia	LK	Sri Lanka	TC	Togo
DE*	Germany	LU	Luxembourg	US	United States of America
DK	Denmark	MC	Monaco		

+ Any designation of "SU" has effect in the Russian Federation. It is not yet known whether any such designation has effect in other States of the former Soviet Union.

- 1 -

TRANSDERMAL DEVICE

The invention relates to a method of preparing a device for transdermal delivery of an active ingredient and to transdermal devices prepared by that method.

The administration of drugs through the skin is a concept which is now well established and this route has several advantages over more conventional forms of drug delivery such as injection or oral ingestion. A particular advantage is that transdermal drug delivery devices can provide a sustained and controlled release of the active ingredient over a prolonged period so that the resulting blood levels remain constant. This is in contrast to other forms of administration where surges of the agent occur in the bloodstream immediately after administration and then drop away rapidly until the next dose is given. In the case of oral administration the blood level is further influenced by contents of the intestines and therefore difficult to control. Transdermal administration permits direct access to the bloodstream without first passage through the gastrointestinal tract and liver and also without the inherent problems associated with injection such as risk of infection and need for sterile administration equipment.

Because of the advantage of transdermal administration, in recent years a very large number of devices have been developed and described for the transdermal administration of a variety of pharmaceuticals. The devices are usually in the form of a patch or plaster to be attached to the skin. Early devices such as for example, that described in U.S. 3,598,122 comprised a reservoir containing the active ingredient, either in solid or liquid form.

- 2 -

The reservoir walls were composed of a material permeable to that ingredient and it was stuck to the skin by a thin layer of adhesive which was also permeable to the active ingredient. The outer
5 surface of the reservoir was covered with a backing material impermeable to the active ingredient. Such devices were bulky and solvents in which the active agent was dissolved tended to interfere with the ability of the adhesive to stick to the skin.

10 With improvements in adhesives available it was soon found possible, and indeed preferable, to prepare transdermal devices in which the adhesive layer itself provided the drug reservoir. Thus more modern transdermal devices usually comprise at least
15 an impermeable backing material, a layer of drug-containing adhesive attached to the backing material and a release liner on the other adhesive surface which is removed for application of the device to the skin. Additional membranes are sometimes included
20 within the device to regulate the rate of passage of the active agent from the adhesive to the skin.

Various methods have been used to achieve suitable drug/adhesive mixtures in which the active ingredient is dispersed in the adhesive without
25 affecting the ability of the adhesive to stick to the skin. One of the earliest drugs to be administered by a transdermal device was nitroglycerin which is used in the treatment of angina pectoris and congestive cardiac failure. Nitroglycerin is well
30 absorbed by the skin and therefore particularly amenable to transdermal administration. Conveniently it is a liquid at room temperature and so the approach that has been taken is to absorb it on to a solid such as lactose which is then dispersed in a
35 polymer adhesive. Such devices are described in, for example U.S. 4,776,850, G.B. 2,081,582, and others.

- 3 -

One of more other "solvents" are sometimes present in the nitroglycerin adhesive mixtures either as permeation enhancers, or for the purpose of "solvent casting" the mixture onto a backing layer.

5 Where the active ingredient to be incorporated into a transdermal device is a solid any solvent for the agent must be carefully chosen to be compatible with the adhesive. In W086/00814 for example the problem is overcome by choosing a single solvent
10 which is both a solvent for the drug and a solvent for the adhesive. However such a method restricts severely the number of different drugs which are compatible with a particular adhesive and also the type of adhesive which can be used.

15 Alternative methods have therefore been used in which a drug/adhesive mixture is prepared which includes a solvent for the drug and a solvent for the adhesive. The mixture is spread onto an appropriate backing material and then dried to
20 evaporate the solvents leaving the drug dispersed in the adhesive in particulate form. A variation of the method is described in W089/07951 in which the solvents for the adhesive are evaporated during a drying stage leaving the drug, in this case
25 oestrogen, dispersed in particulate form in very high boiling point solvents which do not significantly evaporate on drying but which have a low capacity for the drug.

 While the active ingredient can be taken up by
30 the skin from a dispersion of the solid compound, the rate of uptake can be far better controlled if the agent is in a saturated or supersaturated solution, particularly where the solvent has an adequate capacity for the active ingredient. As the
35 ingredient is taken up by the skin more will become dissolved in solution so maintaining a concentration

gradient over a prolonged period which drives uptake through the skin. Transdermal devices are known which contain saturated drug solutions. They are described for example in G.B. 2,156,215 and U.S. 4,201,211. However these documents fail to describe a way in which the level of saturation can be precisely controlled.

The present invention provides an improved method for preparing transdermal devices which contain saturated or supersaturated solutions of an active ingredient within an adhesive layer by use of a carefully selected mixture of solvents and selective evaporation of a particular solvent or solvents by drying at a temperature above the boiling points thereof, to influence the final concentration of the solution of active ingredient in the device.

In accordance with the invention a method of preparing a device for transdermal delivery of an active ingredient which is a solid at room temperature and in which part or all of the active ingredient is present in a saturated or supersaturated solution comprises the steps of:-

- (a) preparing a mixture comprising at least
 - (i) a polymer adhesive
 - (ii) a vehicle for the polymer adhesive
 - (iii) the active ingredient
 - (iv) a solvent mixture for the active ingredient which comprises at least two solvents;
- (b) forming the mixture prepared in step (a) into a film, and
- (c) drying the film prepared in step (b)

- 5 -

wherein the vehicle for the polymer adhesive
and at least one of the solvents in the solvent
mixture for the active ingredient have boiling
points below the drying temperature and at
least one of the solvents in the solvent
mixture for the active ingredient has a boiling
point above the drying temperature and wherein
the solubility of the active ingredient in the
said solvent or solvents having a boiling point
above the drying temperature is greater than
0.5%.

The above method provides a very precise way of
preparing an adhesive/active ingredient mixture which
contains a saturated or supersaturated solution of
the ingredient after drying.

It is to be understood herein that the term
"active ingredient" is intended to mean a single
active agent or a combination of more than one active
agent.

Dissolving the active ingredient in a mixture
of solvents and then drying at a temperature which
facilitates the evaporation of the vehicle for the
adhesive and one of the solvents for the active
ingredient, because it is above their boiling points,
leaves the active ingredient in either a
supersaturated solution in the solvent or solvents
that remain or in a saturated solution with some of
the ingredients precipitated in particulate form.
Saturated and supersaturated solutions are
particularly advantageous from the point of view of
transdermal administration because they assist in
controlling the rate of migration of the active
ingredient through the skin as previously mentioned.

The choice of particular solvents, adhesives
and drying temperatures is dictated by the solubility

of the particular active ingredient in the solvent or solvents remaining in the device after drying. Thus with careful selection of all the components the method of the invention can provide transdermal
5 devices which can administer a very wide range of drugs.

Although the solubility of the active ingredient in the solvent or solvents having a boiling point above the drying temperature need only
10 be greater than 0.5%, preferably it is greater than 1.0%, more preferably greater than 2.5% and most preferably greater than 10%.

The polymer adhesive may be a polyisobutylene or silicone adhesive although acrylate polymer
15 adhesives are particularly preferred. Suitable vehicles for the acrylate adhesives are for example methanol, ethanol, industrial methylated spirits (IMS), isopropanol and water. Suitable vehicles which may be used with polyisobutylene are toluene,
20 xylene and methylene chloride. Suitable vehicles for silicone adhesives are chlorofluorocarbons such as, for example, trichlorotrifluoroethane. For acrylate adhesives aqueous dispersions are preferred. In this latter case drying temperatures used in drying the
25 film must always be in excess of 100°C at normal atmospheric pressures. Where the vehicle for the adhesive is a lower boiling solvent such as methanol (bp 65°C), ethanol (bp 78.5°C) or isopropanol (bp 82.4°C), a lower drying temperature may be used
30 providing it is above the boiling point of the low boiling solvent included in the solvent mixture for the active ingredient.

In one embodiment of the invention the vehicle for the adhesive and the solvent to be evaporated
35 during drying from the solvent mixture for the active ingredient both are chosen to have a boiling point

- 7 -

below that of ethanol. A drying temperature can thus be chosen which allows the ethanol to be maintained within the device. This is advantageous because ethanol is a useful skin permeation enhancer for some
5 drugs. For acrylate systems a suitable solvent which may be evaporated while ethanol is retained is methanol. For non-aqueous systems ether or chlorofluorocarbons may be used.

In another embodiment of the invention the
10 solvent in the solvent mixture for the active ingredient which is evaporated on drying may be ethanol, isopropanol, industrial methylated spirits (IMS) or water.

High boiling point solvents suitable for
15 forming the saturated or supersaturated solutions of the active ingredient in the transdermal device are those having boiling points in excess of 110°C. Preferred solvent mixtures include one or more of diethylene glycol, propylene glycol, propylene
20 carbonate, glycerol, lower molecular weight polyethylene glycols, propylene glycol esters, polyol fatty acid esters, fatty alcohol derivatives, oleic acid, iso-octyl stearate, iso-propyl myristate, isopropyl palmitate, ethyl oleate, diisopropyl
25 adipate, diethylsuccinate, hexylaurate, triglycerides of caprylic or capric acids, diethyltoluamide, laurocapram, n-methylpyrrolidone and diethylene glycol monoether. Also suitable as solvents which are not evaporated from the device on drying are
30 essential oils such as eucalyptus oil, tea-tree oil and lavender oil. Preferably at least one of the solvents which remains in the device will also act as a permeation enhancer to assist uptake by the skin of the active ingredient. Preferred solvent systems are
35 propylene glycol-diethyltoluamide, n-methylpyrrolidone-diethyltoluamide, propylene

glycol - diethylene glycol monoethyl ether and diethyltoluamide-diethylene glycol monoethyl ether - tea tree oil.

Among the active agents which may be included in transdermal devices produced by the method of the invention are anti-histamines such as, for example, clenastine fumarate, steroid hormones such as oestradiol, progestins such as norethisterone acetate, norgestrel, ethynodiol diacetate, medroxy progesterone acetate, gestodene and desogestrel, vasodilators such as nifedipine and diltiazem, antihypertensives such as clonidine and propranolol, bronchodilators such as salbutamol and clenbuterol, anti-tumour agents such as methotrexate and 5-fluouracil, alkaloids such as physostigmine and analgesics such as fentanyl, sufentanil, buprenorphine and hydromorphone. The device may contain an active ingredient which is a combination of more than one of the above active agents, for example an oestrogen with a progestin.

While the solvents to be used in the method of the invention must be selected in order that a saturated or supersaturated solution is produced on drying, solvents may also be selected which modify the properties of the adhesive so that it possesses the required degree of adhesion and tackiness to stick to the skin for the required period, which could be several days, but at the same time can be easily removed as required. The method of the present invention allows polymer adhesives which are normally too aggressive to be used in transdermal devices to be rendered suitable by choice and incorporation of an appropriate solvent mixture.

The assembly of a transdermal device prepared in accordance with the method of the present invention will now be described by way of example

- 9 -

with reference to Figures 1 and 2 of the accompanying drawings and Examples 1 to 4.

Figure 1 is a vertical section through a first embodiment of the invention without the inclusion of
5 a rate control membrane.

Figure 2 is a vertical section through a second embodiment of the invention including a rate control membrane.

Figure 3 shows mean plasma concentration time
10 curves following transdermal administration of norethisterone acetate to four post menopausal women using a transdermal device prepared in accordance with the method of the invention

----- results from samples assayed by RIA at
15 Liverpool University.

x-----x results from same samples assayed by RIA at Hammersmith Hospital.

↓ transdermal patches applied or replaced.

↑ transdermal patches removed.

20 Figure 4 shows mean plasma concentration time curves following transdermal administration of oestadiol using the devices of Example 4 (▲--▲) and known product Estraderm 50 (X--X). The arrows indicate patches applied, replaced or removed as
25 above.

As already described, a mixture is formed which comprises a polymer adhesive in a suitable vehicle, the active ingredient to be administered, and a solvent mixture for the active ingredient which
30 comprises at least two solvents one of which must have a boiling point above the drying temperature and one below. Preferably the active ingredient is first dissolved in the solvent mixture and the solution slowly added to the adhesive polymer previously
35 dispersed in a suitable vehicle. Depending on the coating technique and adhesive used the addition of

- 10 -

an adhesive thickener may be required. The mixture of adhesive polymer and active ingredient is formed into a film, preferably by coating onto a flexible sheet material. A typical embodiment of a device

5 formed in accordance with the method of the invention is shown in Figure 1. The adhesive mixture is formed into a layer 4 on a siliconised release paper 2. The layer is preferably about 10 to 500 μm thick. The coated release paper is dried at the appropriate

10 temperature to drive off the necessary solvents and then laminated to a backing material 6 impermeable to the active ingredient. Suitable siliconised release liners are 3M Health Care Type 660 or 1360, Daubert HDPE 164Z or L. Stace types 635/6. Preferable

15 backing materials include clear polyester film laminate (e.g. 3M Health Care Type 1012 or 1220), metalised skin-tone polyester laminate (e.g. 3M Health Care Type 1109) and co-extruded high barrier films either clear (e.g. BXL Plastics Hybar) or

20 skin-tone (e.g. Grace- Cryovac MF200). Backings having higher oxygen and water vapour transmission rates are preferred for devices intended for treatment for more than 24 hours. A suitable backing material in these circumstances is Semex

25 polyester-urethane film type MF 4387-00.

The reverse manufacturing method is also possible and in some cases advantageous i.e. spreading the adhesive/solvent mixture onto the backing material and then laminating it to the

30 release liner.

Figure 2 shows a second embodiment of the invention in which the adhesive/active ingredient layer is divided by a rate control membrane 8. The layer 4a which, in use, is in direct contact with the

35 skin provides an initial loading dose of the active ingredient. As this migrates into the skin the

consequent concentration difference between layer 4a and 4b causes the layer 4a to be replenished with active ingredient from the layer 4b at a rate dictated by the rate control membrane. Thus the inclusion of such a membrane provides a further means to control the rate of uptake for a pre-determined period, firstly by selection of the appropriate membrane and secondly by varying the thickness of the layers 4a and 4b on either side of the membrane. Suitable materials for forming the rate control membrane include polypropylene film (e.g. Celgard microporous film), polyvinyl acetate film (e.g. Mowiol film (Hoechst) and ethyl vinyl acetate film (e.g. controlled caliper MSP series films obtained from 3M Health Care Speciality Division). The thickness of the layer 4a may be in the range 5 to 50 μm and the thickness of the layer 4b may be in the range 50 to 500 μm .

The device of Figure 2 is formed as previously described except that when using conventional coating/drying equipment the process becomes two stages. The backing material 6, coated with adhesive layer 4b is laminated to rate control membrane 8. The second stage is the lamination of this laminate to the adhesive layer 4a which has been coated on to the release paper 2. Alternative manufacturing methods are possible and more than one rate control membrane can be incorporated at any location within a multilayer device. Preferably all of the above described layers are assembled on a single large sheet which is die cut into transdermal devices of the appropriate size.

Example 1

Transdermal device containing norethisterone acetate without a rate control membrane.

A mixture of acrylate polymer adhesive and the

active ingredient norethisterone acetate is formed containing the following:-

5	<u>Component</u>	<u>Quantity (g)</u>
	Norethisterone acetate (micronised)	395
	Propylene glycol	2125
	Diethyltoluamide	1000
10	Ethanol (95%) or IMS	1500
	Primal N560 (acrylate adhesive dispersion in water)	44500
15	Acrysol ASE 60 (thickener for adhesive diluted 50:50)	<u>480</u>
	Total	<u>50Kg</u>

20 The norethisterone acetate is dissolved in propylene glycol, diethyltoluamide and ethanol by sonication or warming. This solution is added slowly to the aqueous acrylate adhesive dispersion (Primal N560, Rohm & Hass) with mixing. An adhesive thickener (Acrysol ASE 60) is then added to the
 25 mixture as a 50% solution/water mix sufficient to produce a thicker spreading solution of around 800 cP (Brookfield) for reverse roll coating or 60,000 cP to suit knife over roll coating.

30 The mixture is coated on the backing polyester (3M Health Care Type 1109) at about 100 μ m wet coating thickness and dried at about 105°C to drive off the water and the ethanol or IMS from the acrylate adhesive. The resulting dried adhesive layer is about 55 μ m thick. The release liner
 35 (Stace type 636) is laminated to the adhesive layer. The final sheet is die-cut to form transdermal

- 13 -

devices of about 19 or 28.5 cm² each containing 1.5 or 2.25 mg norethisterone acetate respectively, which are packaged individually.

5

Example 2Transdermal device containing oestradiol with rate control membrane.

A mixture is prepared containing the following:-

10	<u>Component</u>	<u>Quantity (g)</u>
	17 β Oestradiol	87.5
	Propylene glycol	400
	Diethyltoluamide	100
15	95% Ethanol or IMS	100
	Polysorbate 20	12.5
	Primal N560 (acrylate adhesive dispersion)	4262.5
	Acrysol ASE 60 (thickener for adhesive) 50:50 water	<u>37.5</u>
20		
	Total	<u>5000g</u>

25 The oestradiol is dissolved in the solvent mixture and slowly added to the aqueous adhesive to which an Acrysol ASE 60 thickener is also added in a similar way to Example 1. The mixture is coated onto a siliconised release liner (3M Health Care Type 660) to give a 50 μ m wet coating which is dried at

30 105°C as described above. When dried the adhesive layer and liner are laminated to a rate control membrane sheet material (3M ethyl vinyl acetate membrane, MSP 987192) which is then coated with a 250 μ m wet coating of the same adhesive mixture and

35 dried as before. The adhesive layers are then laminated to the clear polyester film laminate

backing material as described. The sheets are cut into 20 cm² transdermal devices each containing 10.5 mg oestradiol and individually packaged for use.

5

Example 3Transdermal device containing oestradiol without a rate control membrane

A mixture is prepared containing the following:-

10	<u>Component</u>	<u>Quantity (g)</u>
	17 β oestradiol	440
	Diethyltoluamide	2250
	Isopropanol	60
15	Primal N560	47000
	Acrysol ASE 60:water (50:50)	<u>250</u>
	Total	50Kg

20

The devices are prepared and assembled as described in Example 1. The release liner is coated to a wet-coat thickness of 100 μ m and after drying and laminating the laminate is die cut to 28.5 cm² devices each containing 2.5 mg oestradiol.

25

Example 4Transdermal device containing oestradiol without a rate control membrane

A mixture is prepared containing the following:-

30

35

- 15 -

	<u>Component</u>	<u>Quantity (g)</u>
5	17- β Oestradiol (micronised)	30
	Diethyltoluamide	100
	Diethylsodium sulphosuccinate	3
	Isopropanol/water 50:50	2
	Primal N560	655
10	Primal N582	200
	Acrysol ASE 60:water 50:50	q.s. <u>10</u>
	Total	<u>1000 g</u>

15 The devices are prepared and assembled as described in Example 1 except that the devices are cut to 20cm². Results obtained in a 4 subject pharmacokinetic study in comparison with an existing product (Estraderm 50) are shown in Figure 4.

20

Example 5

Transdermal device containing buprenorphine without a rate control membrane

A mixture is prepared containing the following:-

25

30

35

- 16 -

	<u>Component</u>	<u>Quantity (g)</u>
	Buprenorphine	42
5	Ethanol or IMS	100
	Diethyltoluamide	150
	Diethylene Glycol Monoethyl ether	150
	Tea Tree oil	100
	Primal N560	3908
10	Primal N582	500
	Acrysol ASE 60:water 50:50	<u>50</u>
	Total	<u>5000 g</u>

15 The devices are prepared and assembled as described in Example 1 except that the release liner is coated to a wet coat thickness of 150 μm and after drying the laminate is cut to 20 and 50 cm^2 devices containing 2.5 mg/20 cm^2 or 6.3 mg/50 cm^2 buprenorphine respectively.

20 It is to be noted that the terms Hybar, Cryovac, Celgard, Mowiol, Contran, Primal, Acrysol, Brookfield, Triton and Estraderm, used in the specification are Registered Trade Marks.

25

30

35

CLAIMS:

1. A method of preparing a device for transdermal
5 delivery of an active ingredient which is a solid at
room temperature and in which part or all of the
active ingredient is present in a saturated or
supersaturated solution comprises the steps of:-

- 10 (a) preparing a mixture comprising at least
(i) a polymer adhesive
(ii) a vehicle for the polymer adhesive
(iii) the active ingredient
(iv) a solvent mixture for the active ingredient
15 which comprises at least two solvents;
- (b) forming the mixture prepared in step (a) into a
film, and
- 20 (c) drying the film prepared in step (b)

wherein the vehicle for the polymer adhesive and
at least one of the solvents in the solvent
mixture for the active ingredient have boiling
25 points below the drying temperature and at least
one of the solvents in the solvent mixture for the
active ingredient has a boiling point above the
drying temperature and wherein the solubility of
the active ingredient in the said solvent or
30 solvents having a boiling point above the drying
temperature is greater than 0.5%.

2. A method as claimed in claim 1 wherein the
solubility of the active ingredient in the solvent or
35 solvents having a boiling point above the drying
temperature is greater than 1%.

- 18 -

3. A method as claimed in claim 2 wherein the solubility of the active ingredient in the solvent or solvents having a boiling point above the drying
5 temperature is greater than 10%.

4. A method as claimed in any preceding claim wherein the polymer adhesive is an acrylate polymer
10 adhesive.

5. A method as claimed in any one of claims 1 to 3 wherein the polymer adhesive is a polyisobutylene
adhesive.

15 6. A method as claimed in any one of claims 1 to 3 wherein the polymer adhesive is a silicone adhesive.

7. A method as claimed in claim 4 or claim 5 wherein the vehicle for the polymer adhesive is
20 ethanol, industrial methylated spirits or isopropanol.

8. A method as claimed in claim 5 wherein the vehicle for the polymer adhesive is toluene, xylene or methylene chloride.
25

9. A method as claimed in claim 6 wherein the vehicle for the polymer adhesive is a chlorofluorocarbon.

30 10. A method as claimed in any one of claims 1 to 5 wherein the vehicle for the polymer adhesive is a solvent having a boiling point below that of ethanol.

11. A method as claimed in claim 10 wherein the
35 vehicle for the polymer adhesive is methanol.

- 19 -

12. A method as claimed in claim 4 wherein the vehicle for the polymer adhesive is water.

13. A method as claimed in any one of claims 1, 2, 3, 4, 5, 7 or 12 wherein the solvent in the solvent mixture for the active ingredient with a boiling point below the drying temperature is ethanol or industrial methylated spirits or isopropanol or water.

14. A method as claimed in claim 10 wherein the solvent in the solvent mixture for the active ingredient with a boiling point below the drying temperature is a solvent having a boiling point below that of ethanol.

15. A method as claimed in claim 14 wherein the solvent in the solvent mixture for the active ingredient with a boiling point below the drying temperature is methanol.

16. A method as claimed in any preceding claim wherein the solvent mixture for the active ingredient comprises at least one solvent having a boiling point above the drying temperature selected from diethylene glycol, propylene glycol, propylene carbonate, glycerol, lower molecular weight polyethylene glycols, propylene glycol esters, polyol fatty acid esters, fatty alcohol derivatives, oleic acid, iso-octyl stearate, isopropyl myristate, isopropyl palmitate, ethyl oleate, disopropyl adipate, diethylsuccinate, hexylaurate, triglycerides of caprylic or capric acids, diethyl toluamide, laurocapram, n-methylpyrrolidone, diethylene glycol monoethyl ether or essential oils such as eucalyptus, tea tree or lavender.

- 20 -

17. A method as claimed in any one of claims 7, 12, 13 or 16 wherein the drying step (c) is carried out at or above 100°C.

5 18. A method as claimed in any one of claims 6, 10, 11, 14, 15 or 16 wherein the drying step (c) is carried out at a temperature below the boiling point of ethanol.

10 19. A method as claimed in any preceding claim wherein the active ingredient comprises at least one active agent from the categories antihistamines, steroid hormones, progestins, vasodilators, antihypertensives, bronchodilators, anti-tumour
15 agents, alkaloids or analgesics.

20 20. A method as claimed in any preceding claim wherein the film prepared in step (b) is formed by coating the mixture prepared in step (a) onto a thin flexible sheet material.

21. A method as claimed in claim 20 wherein the thin flexible sheet material is a siliconised release
25 liner.

22. A method as claimed in claim 20 wherein the flexible sheet material is a backing material impermeable to the active ingredient.

30 23. A method as claimed in any one of claims 20 to 22 wherein the film formed in step (b) is between 5µm and 500 µm thick.

35 24. A method as claimed in claim 21 or claim 23 wherein the coated surface of the release liner is laminated to a backing material impermeable to the

- 21 -

active ingredient.

25. A method as claimed in claim 22 or 23 wherein
the coated surface of the impermeable backing
5 material is laminated to a siliconised release liner.

26. A method as claimed in any one of claims 20
to 23 wherein the coated surface of the release liner
or backing material is laminated to a rate control
10 membrane the free surface of which is further coated
with the mixture prepared in step (a).

27. A method as claimed in claim 26 wherein the
coated rate control membrane is laminated to a
15 further rate control membrane or to a siliconised
release liner or backing material impermeable to the
active ingredient.

28. A method as claimed in claim 26 or 27 wherein
20 the thickness of the adhesive/active ingredient layer
on either side of the rate control membrane is varied
to control the rate of migration across the membrane.

29. A method as claimed in claim 26 or 27 wherein
25 the thickness of the adhesive/active ingredient layer
on either side of the rate control membrane is varied
to control the proportion or amount of active
ingredient immediately available adjacent to the skin
for absorption.

30

30. A method as claimed in any one of claims 22
to 29 wherein the backing material impermeable to the
active ingredient is a polyester film laminate,
metalised polyester laminate co-extruded high barrier
35 film or an air and water permeable polyurethane such
as Semex polyester-urethane film type MF 4387-60.

- 22 -

31. A method as claimed in any one of claims 26
to 30 wherein the rate control membrane is a
polypropylene film, a polyvinyl acetate film or an
5 ethylvinyl acetate film.

32. A device for transdermal delivery of an active
ingredient prepared by the method as claimed in any
one of claims 1 to 31.
10

33. A method of preparing a device for
transdermal delivery of an active ingredient
substantially as described herein with reference to
any of Examples 1 to 5.
15

34. A device for transdermal delivery of an
active ingredient as claimed in claim 32 and
substantially as described herein with reference to
Figures 1 and 2 of the accompanying drawings.
20

25

30

35

1/3

FIG. 1.




FIG. 2.




FIG. 3.

Norethisterone
concentration
pg/ml

Patches changed at A





FIG. 4.



INTERNATIONAL SEARCH REPORT

International Publication No

PCT/GB 91/01730

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all)		
According to International Patent Classification (IPC) or to both National Classification and IPC Int.Cl. 5 A61L15/44		
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁷		
Classification System	Classification Symbols	
Int.Cl. 5	A61L ; A61K	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸		
III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹		
Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
X	EP,A,0 371 496 (SCHERING CORPORATION) 6 June 1990 see page 6; claims; table 1 ---	1-25, 32-34
X	PATENT ABSTRACTS OF JAPAN vol. 12, no. 333 (C-526)8 September 1988 & JP,A,63 093 714 (SEKISUI) 25 April 1988 see abstract ---	1
X	PATENT ABSTRACTS OF JAPAN vol. 12, no. 159 (C-495)14 May 1988 & JP,A,62 273 914 (SEKISUI) 28 November 1987 see abstract ---	1
X	PATENT ABSTRACTS OF JAPAN vol. 12, no. 159 (C-495)14 May 1988 & JP,A,62 273 913 (SEKISUI) 28 November 1987 see abstract --- -/-	1
<p>¹⁰ Special categories of cited documents: ¹⁰</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	
10 JANUARY 1992	31. 01. 92	
International Searching Authority	Signature of Authorized Officer	
EUROPEAN PATENT OFFICE	COUSINS -VAN STEEN <i>Planis</i>	

Form PCT/ISA/210 (second sheet) (January 1985)

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category °	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.
A	WO,A,8 907 959 (J.TUCKER) 8 September 1989 cited in the application see page 5, line 13 - line 22; claims; examples ---	1-34
A	EP,A,0 156 080 (NITTO ELECTRIC INDUSTRIAL CO) 2 October 1985 & GB,A,2 156 215 9 October 1985 cited in the application ---	
A	EP,A,0 328 806 (PACO PHARMACEUTICAL SERVICES) 23 August 1989 ----	

**ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO.**

GB 9101730
SA 51828

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information. 10/01/92

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-0371496	06-06-90	AU-A- 4745390 CA-A- 2004203 WO-A- 9006120	26-06-90 01-06-90 14-06-90
WO-A-8907959	08-09-89	AU-A- 3289589 EP-A- 0336543 GB-A- 2232892 JP-T- 3503636	22-09-89 11-10-89 02-01-91 15-08-91
EP-A-0156080	02-10-85	JP-A- 60185713 DE-A, C 3500508 FR-A, B 2560522 GB-A, B 2156215 US-A- 4719226	21-09-85 12-09-85 06-09-85 09-10-85 12-01-88
GB-A-2156215	09-10-85	JP-A- 60185713 DE-A, C 3500508 EP-A, B 0156080 FR-A, B 2560522 US-A- 4719226	21-09-85 12-09-85 02-10-85 06-09-85 12-01-88
EP-A-0328806	23-08-89	US-A- 4906475 AU-A- 1917788 JP-A- 2003607	06-03-90 17-08-89 09-01-90

EPO FORM P0079

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82